GP CCE Cases · cardiovascular-health
Routine cholesterol result in a worried well patient — CCE clinical encounter
CCE-style clinical encounter: a 52-year-old man with an incidental LDL of 4.2 mmol/L, moderate absolute five-year risk, and a brother on 'cholesterol injections'. The candidate must frame absolute risk honestly, initiate statin therapy with quantified benefit, address lifestyle without substituting it for drugs, and recognise the family history as an FH red flag requiring screening.
On this page
Study tools
Target exams
RACGP CCEFRACGP oralsCFPC SOOs
Prompt
A 52-year-old male accountant attends for results: LDL 4.2 mmol/L, HDL 1.1 mmol/L, triglycerides 2.0 mmol/L. Blood pressure 138/86, ex-smoker (quit 3 years), BMI 29. His younger brother recently started 'fortnightly injections' for cholesterol after a stent at age 49. He wants to 'try diet first for six months'. No personal ASCVD history.
Objectives
- Calculate and communicate absolute five-year CVD risk rather than reacting to the LDL number alone. [8]
- Quantify statin benefit with CTT arithmetic — RR 0.78 per mmol/L — so the decision is shared and informed. [1]
- Recognise the premature-brother-stent history as an FH red flag warranting formal assessment. [9]
- Support diet-and-exercise trial honestly while setting review criteria that do not delay indicated therapy. [11]
- Address what "fortnightly injections" likely are — PCSK9 inhibitors — and why his own pathway may differ. [3]
References11ShowHide
- [1]Cholesterol Treatment Trialists’ (CTT) Collaboration, Baigent C, Blackwell L, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials Lancet, 2010.PMID 21067804
- [2]Cholesterol Treatment Trialists' (CTT) Collaborators, Mihaylova B, Emberson J, et al. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials Lancet, 2012.PMID 22607822
- [3]Sabatine MS, Giugliano RP, Keech AC, et al. Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease N Engl J Med, 2017.PMID 28304224
- [4]Schwartz GG, Steg PG, Szarek M, et al. Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome N Engl J Med, 2018.PMID 30403574
- [5]Nissen SE, Lincoff AM, Brennan D, et al. Bempedoic Acid and Cardiovascular Outcomes in Statin-Intolerant Patients N Engl J Med, 2023.PMID 36876740
- [6]Sever PS, Dahlöf B, Poulter NR, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial Lancet, 2003.PMID 12686036
- [7]Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group N Engl J Med, 1995.PMID 7566020
- [8]SCORE2 working group and ESC Cardiovascular risk collaboration SCORE2 risk prediction algorithms: new models to estimate 10-year risk of cardiovascular disease in Europe Eur Heart J, 2021.PMID 34120177
- [9]Casula M, Olmastroni E, Pirillo A, et al. Evaluation of the performance of Dutch Lipid Clinic Network score in an Italian FH population: The LIPIGEN study Atherosclerosis, 2018.PMID 30270079
- [10]Cannon CP, Blazing MA, Giugliano RP, et al. Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes N Engl J Med, 2015.PMID 26039521
- [11]Watts GF, Ooi EM, Chan DC Demystifying the management of hypertriglyceridaemia Nat Rev Cardiol, 2013.PMID 24060958